var data={"title":"Paroxetine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Paroxetine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6727?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=paroxetine-drug-information\" class=\"drug drug_general\">see &quot;Paroxetine: Drug information&quot;</a> and <a href=\"topic.htm?path=paroxetine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Paroxetine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709196\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Suicidality and antidepressant drugs:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Antidepressants increased the risk compared with placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of paroxetine or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared with placebo in adults older than 24 years; there was a reduction in risk with antidepressants compared with placebo in adults 65 years and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Closely observe and appropriately monitor patients of all ages who are started on therapy for clinical worsening, suicidality, or unusual changes in behavior. Advise families and caregivers of the need for close observation and communication with the health care provider. Paroxetine is not approved for use in pediatric patients.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206594\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Brisdelle;</li>\n      <li>Paxil;</li>\n      <li>Paxil CR;</li>\n      <li>Pexeva</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50783091\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Paxil;</li>\n      <li>Paxil CR</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054737\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antidepressant, Selective Serotonin Reuptake Inhibitor (SSRI)</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054730\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=paroxetine-drug-information\" class=\"drug drug_general\">see &quot;Paroxetine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Obsessive-compulsive disorder (OCD):</b> Limited data available: Children and Adolescents 7 to 17 years: Oral: Initial: 10 mg once daily; titrate every 7 to 14 days in 10 mg/day increments; maximum daily dose: 60 mg/<b>day</b>. Dosing based on two trials. The first was a 12-week open-label trial of paroxetine in 20 outpatients 8 to 17 years of age that demonstrated the potential clinical usefulness in pediatric OCD (Rosenberg 1999). The second trial demonstrated efficacy of paroxetine in a 10-week, randomized, double-blind, placebo-controlled trial conducted in 207 pediatric patients (aged 7 to 17 years) with OCD; the overall mean dose was 20.3 mg/day for children and 26.8 mg/day for adolescents (Geller 2004). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Social anxiety disorder: </b> Limited data available: Children and Adolescents 8 to 17 years: Oral: Initial: 10 mg once daily; titrate at intervals of at least 7 days in 10 mg/day increments; maximum daily dose: 50 mg/<b>day</b>. Dosing based on a 16-week multicenter, randomized, double-blind, placebo-controlled trial that reported the efficacy of paroxetine in pediatric patients (aged 8 to 17 years) with social anxiety disorder; 163 patients were randomized to receive paroxetine; the overall mean dose was 21.7 mg/day for children and 26.1 mg/day for adolescents (Wagner 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Discontinuation of therapy:</b> Upon discontinuation of antidepressant therapy, gradually taper the dose to minimize the incidence of withdrawal symptoms and allow for the detection of reemerging symptoms. Evidence supporting ideal taper rates is limited. APA and NICE guidelines suggest tapering therapy over at least several weeks with consideration to the half-life of the antidepressant; antidepressants with a shorter half-life may need to be tapered more conservatively. In addition for long-term treated patients, WFSBP guidelines recommend tapering over 4 to 6 months. If intolerable withdrawal symptoms occur following a dose reduction, consider resuming the previously prescribed dose and/or decrease dose at a more gradual rate (APA 2010; Bauer 2002; Haddad 2001; NCCMH 2010; Schatzberg 2006; Shelton 2001; Warner 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>MAO inhibitor recommendations:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Switching to or from an MAO inhibitor intended to treat psychiatric disorders:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Allow 14 days to elapse between discontinuing an MAO inhibitor intended to treat psychiatric disorders and initiation of paroxetine.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Allow 14 days to elapse between discontinuing paroxetine and initiation of an MAO inhibitor intended to treat psychiatric disorders. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Use with other MAO inhibitors (linezolid or IV methylene blue): </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Do not initiate paroxetine in patients receiving linezolid or IV methylene blue; consider other interventions for psychiatric condition. </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">If urgent treatment with linezolid or IV methylene blue is required in a patient already receiving paroxetine and potential benefits outweigh potential risks, discontinue paroxetine promptly and administer linezolid or IV methylene blue. Monitor for serotonin syndrome for 2 weeks or until 24 hours after the last dose of linezolid or IV methylene blue, whichever comes first. May resume paroxetine 24 hours after the last dose of linezolid or IV methylene blue</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Adult: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Major depressive disorder (MDD):</b>  Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Paxil, Pexeva: Initial: 20 mg once daily, preferably in the morning; increase if needed by 10 mg/day increments at intervals of at least 1 week; maximum daily dose: 50 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Paxil CR: Initial: 25 mg once daily; increase if needed by 12.5 mg/day increments at intervals of at least 1 week; maximum daily dose: 62.5 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Generalized anxiety disorder (GAD):</b> Paxil, Pexeva: Oral: Initial: 20 mg once daily, preferably in the morning; if dose is increased, adjust in increments of 10 mg/day at 1-week intervals; doses of 20-50 mg/day were used in clinical trials; however, no greater benefit was seen with doses &gt;20 mg. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Obsessive compulsive disorder (OCD):</b> Paxil, Pexeva: Oral: Initial: 20 mg once daily, preferably in the morning; increase if needed by 10 mg/day increments at intervals of at least 1 week; recommended dose: 40 mg/day; range: 20 to 60 mg/day; maximum daily dose: 60 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Panic disorder:</b>  Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Paxil, Pexeva: Initial: 10 mg once daily, preferably in the morning; increase if needed by 10 mg/day increments at intervals of at least 1 week; recommended dose: 40 mg/day; range: 10 to 60 mg/day; maximum daily dose: 60 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Paxil CR: Initial: 12.5 mg once daily, preferably in the morning; increase if needed by 12.5 mg/day increments at intervals of at least 1 week; maximum daily dose: 75 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Post-traumatic stress disorder (PTSD):</b> Paxil: Oral: Initial: 20 mg once daily, preferably in the morning;  increase if needed by 10 mg/day increments at intervals of at least 1 week; range: 20 to 50 mg/day. Limited data suggest doses of 40 mg/day were not more efficacious than 20 mg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Premenstrual dysphoric disorder:</b> Paxil CR: Oral: Initial: 12.5 mg once daily in the morning; may be increased to 25 mg/day; dosing changes should occur at intervals of at least 1 week; may be given daily throughout the menstrual cycle <b>or</b> limited to the luteal phase </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Social anxiety disorder:</b>  Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Paxil: Initial: 20 mg once daily, preferably in the morning; recommended dose: 20 mg/day; range: 20 to 60 mg/day; doses &gt;20 mg may not have additional benefit  </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Paxil CR: Initial: 12.5 mg once daily, preferably in the morning; may be increased by 12.5 mg/day increments at intervals of at least 1 week; maximum daily dose: 37.5 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Vasomotor symptoms of menopause:</b> Brisdelle: Oral: 7.5 mg once daily at bedtime. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Discontinuation of therapy:</b> Upon discontinuation of antidepressant therapy, gradually taper the dose to minimize the incidence of withdrawal symptoms and allow for the detection of reemerging symptoms. Evidence supporting ideal taper rates is limited. APA and NICE guidelines suggest tapering therapy over at least several weeks with consideration to the half-life of the antidepressant; antidepressants with a shorter half-life may need to be tapered more conservatively. In addition, for long-term treated patients, WFSBP guidelines recommend tapering over 4-6 months. If intolerable withdrawal symptoms occur following a dose reduction, consider resuming the previously prescribed dose and/or decrease dose at a more gradual rate (APA 2010; Bauer 2002; Haddad 2001; NCCMH 2010; Schatzberg 2006; Shelton 2001; Warner 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>MAO inhibitor recommendations: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Switching to or from an MAO inhibitor intended to treat psychiatric disorders:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Allow 14 days to elapse between discontinuing an MAO inhibitor intended to treat psychiatric disorders and initiation of paroxetine.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Allow 14 days to elapse between discontinuing paroxetine and initiation of an MAO inhibitor intended to treat psychiatric disorders. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Use with other MAO inhibitors (linezolid or IV methylene blue): </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Do not initiate paroxetine in patients receiving linezolid or IV methylene blue; consider other interventions for psychiatric condition. </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">If urgent treatment with linezolid or IV methylene blue is required in a patient already receiving paroxetine and potential benefits outweigh potential risks, discontinue paroxetine promptly and administer linezolid or IV methylene blue. Monitor for serotonin syndrome for 2 weeks or until 24 hours after the last dose of linezolid or IV methylene blue, whichever comes first. May resume paroxetine 24 hours after the last dose of linezolid or IV methylene blue. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosing adjustment in renal impairment:</b> Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Brisdelle:  No dosage adjustments necessary</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Paxil, Paxil CR, Pexeva:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">CrCl &gt;60 mL/minute: No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">CrCl 30 to 60 mL/minute: Plasma concentration is 2 times that seen in normal function. There are no dosage adjustments provided in manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Severe impairment (CrCl &lt;30 mL/minute): Mean plasma concentration is ~4 times that seen in normal function. </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Paxil, Pexeva: Initial: 10 mg/day; increase if needed by 10 mg/day increments at intervals of at least 1 week; maximum dose: 40 mg/day </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Paxil CR: Initial: 12.5 mg/day; increase if needed by 12.5 mg/day increments at intervals of at least 1 week; maximum dose: 50 mg/day </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Adults: In hepatic dysfunction, plasma concentration is 2 times that seen in normal function.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Brisdelle:  No dosage adjustments necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Paxil, Paxil CR, Pexeva:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Mild to moderate impairment: There are no dosage adjustments provided in manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Severe impairment:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Paxil, Pexeva: Initial: 10 mg/day; increase if needed by 10 mg/day increments at intervals of at least 1 week; maximum dose: 40 mg/day </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Paxil CR: Initial: 12.5 mg/day; increase if needed by 12.5 mg/day increments at intervals of at least 1 week; maximum dose: 50 mg/day </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206567\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral, as mesylate [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Brisdelle: 7.5 mg [contains fd&amp;c red #40, fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 7.5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Oral, as hydrochloride [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Paxil: 10 mg/5 mL (250 mL) [contains fd&amp;c yellow #6 aluminum lake, methylparaben, propylene glycol, propylparaben, saccharin sodium; orange flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as hydrochloride [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Paxil: 10 mg, 20 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Paxil: 30 mg, 40 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg, 20 mg, 30 mg, 40 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as mesylate [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pexeva: 10 mg, 20 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pexeva: 20 mg [DSC] [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pexeva: 30 mg, 40 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release 24 Hour, Oral, as hydrochloride [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Paxil CR: 12.5 mg [contains fd&amp;c yellow #10 aluminum lake, fd&amp;c yellow #6 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Paxil CR: 25 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Paxil CR: 37.5 mg [contains fd&amp;c blue #2 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 12.5 mg, 25 mg, 37.5 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206551\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874764\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Brisdelle:<a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204516s004lbl.pdf#page=22&amp;token=3IY+EjihOOErt0+6Gne8beRBQlmGyRprDD2efYjhhc9XfWSls271OLrctObjGFOJmRYWingo7kshRbyfBnzRV0F5YncKFsfsevXB3SROLm3pibVCaXT14jTfradY4DEA&amp;TOPIC_ID=12681\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204516s004lbl.pdf#page=22</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Paxil: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020031s074lbl.pdf#page=43&amp;token=8RuZEY3pTb+sgM/KlYwfnn6c6j4bjljbX6Ql0L/YfbztxhaVXc10fTpsDYPTMaETKLQd8fS2rXCCWRbDZZe7MlwBmIG1mnxKaKab23v1WTdU+bSX+549eUmWf8Eama6m&amp;TOPIC_ID=12681\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020031s074lbl.pdf#page=43</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Paxil CR: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020936s053lbl.pdf#page=44&amp;token=y/0Vj7e4VMzWb3oWMg/dIL1s+7Vhr12BI+BodIj3vW7OUo2fRfulQI6X19EMuCSZIerhsDH4nMk6ptdU4OyZvdvLF0WQaRe4qTslAzcgYlu1P/IGIvGQJujrDcyG9sO5&amp;TOPIC_ID=12681\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020936s053lbl.pdf#page=44</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pexeva: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021299s033lbl.pdf#page=38&amp;token=bXDdZxpqh77ZvvCJgsQvQqrqs53tqvVLGqxeDT7wAXJZAynFLfXLJHxXsvRmB9HNPbL1PtnniuxbMXnpaOJIik2ph1nw+nXXTsWXM3wbIU6MpFiVEA/419WOML7E9Iv7&amp;TOPIC_ID=12681\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021299s033lbl.pdf#page=38</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054741\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">May be administered without regard to meals; administration with food may decrease GI side effects; shake suspension well before use. Paxil, Paxil CR, and Pexeva should preferentially be administered in the morning; whereas Brisdelle is recommended to be administered at bedtime. Do not chew or crush immediate or controlled release tablet, swallow whole</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49104563\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 3]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206588\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsules: Store between 20&deg;C and 25&deg;C (68&deg;F and 77&deg;F); excursions permitted between 15&deg;C and 30&deg;C (59&deg;F and 86&deg;F). Protect from light and humidity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablets: Store immediate-release tablets between 15&deg;C and 30&deg;C (59&deg;F and 86&deg;F) and controlled-release tablets at or below 25&deg;C (77&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension: Store at or below 25&deg;C (77&deg;F). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054740\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brisdelle: Treatment of moderate to severe vasomotor symptoms associated with menopause (FDA approved in adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paxil: Treatment of major depressive disorder (MDD), panic disorder (with or without agoraphobia), obsessive-compulsive disorder (OCD), social anxiety disorder (social phobia), generalized anxiety disorder (GAD), and post-traumatic stress disorder (PTSD) (All indications: FDA approved in adults); has also been used for self-injurious behavior  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Paxil CR: Treatment of major depressive disorder (MDD), panic disorder (with or without agoraphobia), social anxiety disorder (social phobia), and premenstrual dysphoric disorder (PMDD) (FDA approved in adults) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Pexeva: Treatment of major depressive disorder (MDD), obsessive-compulsive disorder (OCD), panic disorder (with or without agoraphobia), and generalized anxiety disorder (GAD) (FDA approved in adults) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206646\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">PARoxetine may be confused with FLUoxetine, PACLitaxel, piroxicam, pyridoxine, vortioxetine</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Paxil may be confused with Doxil, PACLitaxel, Plavix, PROzac, Taxol</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Pexeva may be confused with Lexiva</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Paroxetine is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) due to its strong anticholinergic properties and potential for sedation and orthostatic hypotension. Because of their association with falls and fractures, the selective serotonin reuptake inhibitors (SSRIs) should be avoided in patients 65 years and older with a history of falls or fractures. In addition, use the SSRIs with caution due to their potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206643\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Chest pain, hypertension, palpitations, tachycardia, vasodilatation </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Abnormal dreams, agitation, amnesia, anxiety, chills, confusion, depersonalization, dizziness, drowsiness, emotional lability, fatigue, headache, insomnia, lack of concentration, myasthenia, myoclonus, nervousness, paresthesia, vertigo, yawning </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Diaphoresis, pruritus, skin rash </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Decreased libido, weight gain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Abdominal pain, constipation, decreased appetite, diarrhea, dysgeusia, dyspepsia, flatulence, increased appetite, nausea, vomiting, xerostomia </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Dysmenorrhea, ejaculatory disorder, female genital tract disease, impotence, male genital disease, orgasm disturbance, urinary frequency, urinary tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Infection: Infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Arthralgia, back pain, myalgia, myopathy, tremor, weakness </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ophthalmic: Blurred vision, visual disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Otic: Tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Dyspnea, pharyngitis, rhinitis, sinusitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Abnormal erythrocytes, abnormal hepatic function tests, acute renal failure, adrenergic syndrome, agranulocytosis, akathisia, akinesia, anaphylactoid reaction, anaphylaxis, anemia (various), angina pectoris, angioedema, angle-closure glaucoma, aphasia, aphthous stomatitis, aplastic anemia, asthma, atrial fibrillation, bloody diarrhea, bone marrow aplasia, bradycardia, bronchitis, bulimia nervosa, bundle branch block, cardiac failure, cataract, cellulitis, cerebral ischemia, cerebrovascular accident, change in platelet count, cholelithiasis, colitis, deafness, dehydration, delirium, depression, diabetes mellitus, disorientation, drug dependence, dyskinesia, dysphagia, dystonia, eclampsia, emphysema, esophageal achalasia, exfoliative dermatitis, extrapyramidal reaction, fecal impaction, fungal dermatitis, gastroenteritis, goiter, Guillain-Barre syndrome, hallucination, hematemesis, hematologic disease, hematoma, hemoptysis, hemorrhage (eye, gingival, rectal, retinal, vaginal), hemorrhagic pancreatitis, hepatic failure, hepatic necrosis, hepatitis, hepatotoxicity, homicidal ideation, hyperbilirubinemia, hypercholesteremia, hypergammaglobulinemia, hyperglycemia, hyperhidrosis, hypersensitivity reaction, hyperthyroidism, hypoglycemia, hyponatremia, hypotension, hypothyroidism, immune thrombocytopenia, increased blood urea nitrogen, increased creatine phosphokinase, increased lactate dehydrogenase, increased serum alkaline phosphatase, intestinal obstruction, ischemic heart disease, jaundice, ketosis, low cardiac output, lymphadenopathy, meningitis, migraine, mydriasis, myelitis, myocardial infarction, neuroleptic malignant syndrome (Stevens, 2008), neuropathy, nodal arrhythmia, osteoarthritis, osteoporosis, pancreatitis, pancytopenia, peptic ulcer, peritonitis, phlebitis, pneumonia, prolonged bleeding time, pulmonary edema, pulmonary embolism, pulmonary fibrosis, pulmonary hypertension, restlessness, seizure, sepsis, serotonin syndrome, status epilepticus, Stevens-Johnson syndrome, suicidal ideation, suicidal tendencies, syncope, tetany, thrombophlebitis, thrombosis, torsades de pointes, toxic epidermal necrolysis, uncontrolled diabetes mellitus, vasculitis, ventricular arrhythmia, ventricular fibrillation, ventricular tachycardia, withdrawal syndrome (including increased dreaming/nightmares, muscle cramps/spasms/twitching, headache, nervousness/anxiety, fatigue/tiredness, restless feeling in legs, and trouble sleeping/insomnia)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206574\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Concurrent use with or within 14 days of MAOIs intended to treat psychiatric disorders; initiation in patients being treated with linezolid or methylene blue IV; concomitant use with pimozide or thioridazine; hypersensitivity to paroxetine or any of its inactive ingredients; pregnancy (Brisdelle only).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206555\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Major psychiatric warnings:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Suicidal thinking/behavior: <b>[US Boxed Warning]: Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults (18 to 24 years of age) with major depressive disorder (MDD) and other psychiatric disorders; </b>consider risk prior to prescribing. Short-term studies did not show an increased risk in patients &gt;24 years of age and showed a decreased risk in patients &ge;65 years. Closely monitor patients for clinical worsening, suicidality, or unusual changes in behavior, particularly during the initial 1 to 2 months of therapy or during periods of dosage adjustments (increases or decreases); the patient's family or caregiver should be instructed to closely observe the patient and communicate condition with healthcare provider. A medication guide concerning the use of antidepressants should be dispensed with each prescription. <b>Paroxetine is not FDA approved for use in children.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; The possibility of a suicide attempt is inherent in major depression and may persist until remission occurs. Worsening depression and severe abrupt suicidality that are not part of the presenting symptoms may require discontinuation or modification of drug therapy. Use caution in high-risk patients during initiation of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Prescriptions should be written for the smallest quantity consistent with good patient care. The patient's family or caregiver should be alerted to monitor patients for the emergence of suicidality and associated behaviors such as anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, akathisia, hypomania, and mania; patients should be instructed to notify their healthcare provider if any of these symptoms or worsening depression or psychosis occur.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Akathisia: Inability to remain still due to feelings of agitation or restlessness has been observed with paroxetine and other SSRIs. Usually occurs within the first few weeks of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anticholinergic effects: Has low potential for sedation and anticholinergic effects relative to cyclic antidepressants; however among the SSRI class these effects are relatively higher.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding risk: May impair platelet aggregation resulting in increased risk of bleeding events, particularly if used concomitantly with aspirin, NSAIDs, warfarin or other anticoagulants. Bleeding related to SSRI use has been reported to range from relatively minor bruising and epistaxis to life-threatening hemorrhage.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fractures: Bone fractures have been associated with antidepressant treatment. Consider the possibility of a fragility fracture if an antidepressant-treated patient presents with unexplained bone pain, point tenderness, swelling, or bruising (Rabenda 2013; Rizzoli, 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular effects: May cause mild pupillary dilation, which can lead to an episode of narrow-angle glaucoma in susceptible individuals. Consider evaluating patients who have not had an iridectomy for narrow-angle glaucoma risk factors.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Serotonin syndrome: Potentially life-threatening serotonin syndrome (SS) has occurred with serotonergic agents (eg, SSRIs, SNRIs), particularly when used in combination with other serotonergic agents (eg, triptans, TCAs, fentanyl, lithium, tramadol, buspirone, St John's wort, tryptophan) or agents that impair metabolism of serotonin (eg, MAO inhibitors intended to treat psychiatric disorders, other MAO inhibitors [ie, linezolid and intravenous methylene blue]). Monitor patients closely for signs of SS such as mental status changes (eg, agitation, hallucinations, delirium, coma); autonomic instability (eg, tachycardia, labile blood pressure, diaphoresis); neuromuscular changes (eg, tremor, rigidity, myoclonus); GI symptoms (eg, nausea, vomiting, diarrhea); and/or seizures. Discontinue treatment (and any concomitant serotonergic agent) immediately if signs/symptoms arise.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sexual dysfunction: May cause or exacerbate sexual dysfunction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; SIADH and hyponatremia: SSRIs and SNRIs have been associated with the development of SIADH; hyponatremia has been reported rarely (including severe cases with serum sodium &lt;110 mmol/L), predominately in the elderly. Volume depletion and/or concurrent use of diuretics likely increases risk.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease; paroxetine has not been systemically evaluated in patients with a recent history of MI or unstable heart disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; clearance is decreased and plasma concentrations are increased; a lower dosage may be needed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Mania/hypomania: May worsen psychosis in some patients or precipitate a shift to mania or hypomania in patients with bipolar disorder. Monotherapy in patients with bipolar disorder should be avoided. Patients presenting with depressive symptoms should be screened for bipolar disorder. <b>Paroxetine is not FDA approved for the treatment of bipolar depression.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; clearance is decreased and plasma concentrations are increased; a lower dosage may be needed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorder: Use with caution in patients with a previous seizure disorder or condition predisposing to seizures such as brain damage or alcoholism.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Brisdelle: Brisdelle contains a lower dose than what is required for the treatment of psychiatric conditions. Patients who require paroxetine for the treatment of psychiatric conditions should discontinue Brisdelle and begin treatment with a paroxetine-containing medication which provides an adequate dosage.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley, 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Discontinuation syndrome: Abrupt discontinuation or interruption of antidepressant therapy has been associated with a discontinuation syndrome. Symptoms arising may vary with antidepressant however commonly include nausea, vomiting, diarrhea, headaches, lightheadedness, dizziness, diminished appetite, sweating, chills, tremors, paresthesias, fatigue, somnolence, and sleep disturbances (eg, vivid dreams, insomnia). Less common symptoms include electric shock-like sensations, cardiac arrhythmias (more common with tricyclic antidepressants), myalgias, parkinsonism, arthralgias, and balance difficulties. Psychological symptoms may also emerge such as agitation, anxiety, akathisia, panic attacks, irritability, aggressiveness, worsening of mood, dysphoria, mood lability, hyperactivity, mania/hypomania, depersonalization, decreased concentration, slowed thinking, confusion, and memory or concentration difficulties. Greater risks for developing a discontinuation syndrome have been associated with antidepressants with shorter half-lives, longer durations of treatment, and abrupt discontinuation. For antidepressants of short or intermediate half-lives, symptoms may emerge within 2 to 5 days after treatment discontinuation and last 7 to 14 days (APA 2010; Fava 2006; Haddod 2001; Shelton 2001; Warner 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Electroconvulsive therapy: May increase the risks associated with electroconvulsive therapy; consider discontinuing, when possible, prior to ECT treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26045849\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">The FDA recommends that paroxetine not be used in pediatric patients for the treatment of depression. Three well-controlled trials in pediatric patients with depression have failed to show therapeutic superiority over placebo; in addition, an increased risk for suicidal behavior was observed in patients receiving paroxetine when compared to other SSRIs (Dopheide, 2006). SSRI-associated behavioral activation (ie, restlessness, hyperkinesis, hyperactivity, agitation) is two- to threefold more prevalent in children compared to adolescents; it is more prevalent in adolescents compared to adults. Somnolence (including sedation and drowsiness) is more common in adults compared to children and adolescents (Safer, 2006).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">An SSRI discontinuation syndrome similar to that described in adults has been reported in six children (Diler, 2002). May cause abnormal bleeding (eg, ecchymosis, purpura, upper GI bleeding); use with caution in patients with impaired platelet aggregation and with concurrent use of aspirin, NSAIDs, or other drugs that affect coagulation. A recent report describes five children (age: 8 to 15 years) who developed epistaxis (n=4) or bruising (n=1) while receiving SSRI therapy (sertraline) (Lake, 2000). SSRI-associated vomiting is two- to threefold more prevalent in children compared to adolescents and is more prevalent in adolescents compared to adults (Safer, 2006).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP, 1997; Shehab, 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206630\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2D6 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2C9 (weak), CYP2D6 (strong)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206560\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12681&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the antiplatelet effect of other Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. Management: Patients receiving selective serotonin reuptake inhibitors should be advised to avoid alcohol.  Monitor for increased psychomotor impairment in patients who consume alcohol during treatment with selective serotonin reuptake inhibitors.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifampridine: May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, both drugs have the potential to decrease the seizure threshold, possibly increasing the risk for seizures.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Amphetamines. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antiemetics (5HT3 Antagonists): May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents: Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Apixaban: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Apixaban. Specifically, the risk for bleeding may be increased.  Management: Carefully consider risks and benefits of this combination and monitor closely.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: PARoxetine may decrease the serum concentration of Aprepitant. Aprepitant may decrease the serum concentration of PARoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ARIPiprazole: PARoxetine may enhance the adverse/toxic effect of ARIPiprazole. Specifically, the risk of neuroleptic malignant syndrome may be increased. ARIPiprazole may enhance the serotonergic effect of PARoxetine. This could result in serotonin syndrome. PARoxetine may increase the serum concentration of ARIPiprazole.  Management: Aripiprazole dose adjustment is recommended, except when used adjunctively for depression. Consult full interaction monograph or aripiprazole prescribing information for complete details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ARIPiprazole Lauroxil: CYP2D6 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of ARIPiprazole Lauroxil.  Management: Please refer to the full interaction monograph for details concerning the recommended dose adjustments.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Asenapine: PARoxetine may enhance the QTc-prolonging effect of Asenapine. Asenapine may increase the serum concentration of PARoxetine. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aspirin: Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Aspirin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Asunaprevir: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtoMOXetine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of AtoMOXetine.  Management: Initiate atomoxetine at a reduced dose (adult doses -- patients up to 70kg: 0.5mg/kg/day; patients 70kg or more: 40mg/day) in patients receiving a strong CYP2D6 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benzhydrocodone: CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Benzhydrocodone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Beta-Blockers. <b> Exceptions: </b>Acebutolol; Atenolol; Betaxolol (Ophthalmic); Betaxolol (Systemic); Bisoprolol; Carteolol (Ophthalmic); Esmolol; Labetalol; Levobunolol; Metipranolol; Nadolol; Penbutolol; Sotalol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Glucose Lowering Agents: Selective Serotonin Reuptake Inhibitors may enhance the hypoglycemic effect of Blood Glucose Lowering Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brexpiprazole: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Brexpiprazole.  Management: Reduce brexpiprazole dose to 50% of usual with a strong CYP2D6 inhibitor; this recommendation does not apply if treating major depressive disorder.  Reduce to 25% of usual if used with both a strong CYP2D6 inhibitor and a CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BuPROPion: May enhance the adverse/toxic effect of PARoxetine. BuPROPion may increase the serum concentration of PARoxetine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BusPIRone: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome. Selective Serotonin Reuptake Inhibitors may decrease the metabolism of BusPIRone. Management: The combination of a selective serotonin reuptake inhibitor and buspirone should be undertaken with great caution.  When combined treatment is clinically indicated, monitor closely for signs of serotonin toxicity/serotonin syndrome.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalothin: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Cephalothin. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cimetidine: May decrease the metabolism of Selective Serotonin Reuptake Inhibitors.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clarithromycin: May enhance the adverse/toxic effect of PARoxetine. Clarithromycin may enhance the QTc-prolonging effect of PARoxetine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobicistat: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Codeine: CYP2D6 Inhibitors (Strong) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Substrates (High risk with Inhibitors): CYP2D6 Inhibitors (Strong) may decrease the metabolism of CYP2D6 Substrates (High risk with Inhibitors). <b> Exceptions: </b>Ajmaline; Dapoxetine; Indoramin; Tamoxifen; Timolol (Ophthalmic); Tropisetron.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cyproheptadine: May diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapoxetine: May enhance the adverse/toxic effect of Serotonin Modulators.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Darunavir: May decrease the serum concentration of PARoxetine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deoxycholic Acid: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desmopressin: Selective Serotonin Reuptake Inhibitors may enhance the adverse/toxic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deutetrabenazine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Deutetrabenazine.  Management: The total daily dose of deutetrabenazine should not exceed 36 mg, and the maximum single dose of deutetrabenazine should not exceed 18 mg with concurrent use of a strong CYP2D6 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dextromethorphan: Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Dextromethorphan. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Dextromethorphan.  Management: Avoid the concurrent use of dextromethorphan and SSRIs, particularly fluoxetine and paroxetine, when possible.  The risk for this interaction may persist for several weeks following discontinuation of fluoxetine or paroxetine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dosulepin: Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Dosulepin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DOXOrubicin (Conventional): CYP2D6 Inhibitors (Strong) may increase the serum concentration of DOXOrubicin (Conventional).  Management: Seek alternatives to strong CYP2D6 inhibitors in patients treated with doxorubicin whenever possible.  One U.S. manufacturer (Pfizer Inc.) recommends that these combinations be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: May enhance the serotonergic effect of PARoxetine. This could result in serotonin syndrome. PARoxetine may increase the serum concentration of DULoxetine. Management: Coadminister with caution.  If duloxetine and paroxetine are used in combination, monitor for signs and symptoms of serotonin toxicity/serotonin syndrome, as well as other toxic effects of duloxetine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Edoxaban: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Edoxaban. Specifically, the risk of bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eliglustat: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Eliglustat.  Management: Reduce the eliglustat dose to 84 mg daily. Avoid use of eliglustat in combination with a strong CYP2D6 inhibitor and a strong or moderate CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosamprenavir: May decrease the serum concentration of PARoxetine. The active metabolite amprenavir is likely responsible for this effect.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: PARoxetine may decrease serum concentrations of the active metabolite(s) of Fosaprepitant. Fosaprepitant may decrease the serum concentration of PARoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Galantamine: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of Galantamine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of HYDROcodone. Specifically, concentrations of hydromorphone may be decreased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibritumomab Tiuxetan: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to impaired platelet function and an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibrutinib: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iloperidone: CYP2D6 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolite P88 may be increased. CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolite P95 may be decreased. CYP2D6 Inhibitors (Strong) may increase the serum concentration of Iloperidone.  Management: Reduce iloperidone dose by half when administered with a strong CYP2D6 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Imatinib: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indoramin: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Indoramin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iobenguane I 123: Selective Serotonin Reuptake Inhibitors may diminish the therapeutic effect of Iobenguane I 123. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ioflupane I 123: Selective Serotonin Reuptake Inhibitors may diminish the diagnostic effect of Ioflupane I 123. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limaprost: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Linezolid: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lithium: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could increase the risk of serotonin toxicity/serotonin syndrome. Management: This combination should be undertaken with great caution.  When combined treatment is clinically indicated, monitor closely for signs of serotonin toxicity/serotonin syndrome.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mequitazine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Mequitazine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metaxalone: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylene Blue: Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylene Blue: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May enhance the adverse/toxic effect of Serotonin Modulators. Specifically, the risk of serotonin syndrome or serotonin toxicity may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metoclopramide: May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Management: Seek alternatives to this combination when possible. Monitor patients receiving metoclopramide with selective serotonin reuptake inhibitors for signs of extrapyramidal symptoms, neuroleptic malignant syndrome, and serotonin syndrome.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.  Management: Consider an alternative for one of the interacting drugs in order to avoid metoprolol toxicity. If the combination must be used, monitor response to metoprolol closely. Metoprolol dose reductions may be necessary.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mexiletine: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of Mexiletine. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.  While methylene blue and linezolid are expected to interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors.  Refer to monographs specific to those agents for details.<b> Exceptions: </b>Linezolid; Methylene Blue; Tedizolid.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nebivolol: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Nebivolol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: CYP2D6 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Nicergoline. Specifically, concentrations of the MMDL metabolite may be increased. CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Nicergoline. Specifically, concentrations of the MDL metabolite may be decreased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective): Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective). Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents (Nonselective): Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective). Nonsteroidal Anti-Inflammatory Agents (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors.  Management: Consider using alternative analgesics, when appropriate, and/or addition of a gastroprotective agent.  Monitor patients closely for signs/symptoms of bleeding, and for evidence of diminished SSRI effectiveness with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Panobinostat: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent use of sensitive CYP2D6 substrates when possible, particularly those substrates with a narrow therapeutic index.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perhexiline: CYP2D6 Inhibitors may increase the serum concentration of Perhexiline.  Management: Consider alternatives to this combination if possible. If combined, monitor for increased perhexiline serum concentrations and toxicities (eg, hypoglycemia, neuropathy, liver dysfunction). Perhexiline dose reductions will likely be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimozide: Selective Serotonin Reuptake Inhibitors may enhance the adverse/toxic effect of Pimozide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimozide: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Pimozide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Pitolisant. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pravastatin: May enhance the adverse/toxic effect of PARoxetine. Specifically, blood glucose elevations may occur with the combination.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propafenone: PARoxetine may increase the serum concentration of Propafenone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.<b> Exceptions: </b>Nicergoline; Tedizolid.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin Reuptake Inhibitor/Antagonists: Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Serotonin Reuptake Inhibitor/Antagonists. This may cause serotonin syndrome.  Management: Consider alternatives, and use conservative initial dosing.  Monitor patients receiving these combinations for signs/symptoms of serotonin toxicity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tamoxifen: CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, strong CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tamsulosin: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Tamsulosin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tedizolid: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrabenazine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Tetrabenazine. Specifically, concentrations of the active alpha- and beta-dihydrotetrabenazine metabolites may be increased.  Management: Tetrabenazine adult dose should be reduced by 50% when starting a strong CYP2D6 inhibitor.  Maximum tetrabenazine adult dose is 50 mg/day when used with a strong CYP2D6 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: Selective Serotonin Reuptake Inhibitors may enhance the hyponatremic effect of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thioridazine: CYP2D6 Inhibitors may increase the serum concentration of Thioridazine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thyroid Products: Selective Serotonin Reuptake Inhibitors may diminish the therapeutic effect of Thyroid Products. Thyroid product dose requirements may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Timolol (Ophthalmic): CYP2D6 Inhibitors (Strong) may increase the serum concentration of Timolol (Ophthalmic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TraMADol: CYP2D6 Inhibitors (Strong) may diminish the therapeutic effect of TraMADol. CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of TraMADol. CYP2D6 Inhibitors (Strong) may increase the serum concentration of TraMADol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TraMADol: Serotonin Modulators may enhance the adverse/toxic effect of TraMADol. The risk of seizures may be increased. TraMADol may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants: PARoxetine may enhance the adverse/toxic effect of Tricyclic Antidepressants. PARoxetine may increase the serum concentration of Tricyclic Antidepressants.  Management: Consider alternatives to this combination when possible.  Monitor for adverse effects of tricyclic antidepressants (TCAs), including serotonin syndrome and QT-interval prolongation, when a TCA is being used in combination with paroxetine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tropisetron: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Tropisetron. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tryptophan: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urokinase: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Valbenazine: CYP2D6 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Valbenazine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin E (Systemic): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Selective Serotonin Reuptake Inhibitors may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vortioxetine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Vortioxetine.  Management: The vortioxetine dose should be reduced by 50% when used together with a strong CYP2D6 inhibitor.  Following cessation of the strong CYP2D6 inhibitor, the vortioxetine dose should be returned to the normal level.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206589\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Peak concentration is increased, but bioavailability is not significantly altered by food. Management: Administer without regard to meals. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206562\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D/X (product specific) (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206578\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Paroxetine crosses the placenta (Hendrick Stowe 2003). An increased risk of teratogenic effects, including cardiovascular defects, may be associated with maternal use of paroxetine or other SSRIs; however, available information is conflicting. Nonteratogenic effects in the newborn following SSRI/SNRI exposure late in the third trimester include respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hypo- or hypertonia, hyper-reflexia, jitteriness, irritability, constant crying, and tremor. Symptoms may be due to the toxicity of the SSRIs/SNRIs or a discontinuation syndrome and may be consistent with serotonin syndrome associated with SSRI treatment. Persistent pulmonary hypertension of the newborn (PPHN) has also been reported with SSRI exposure. The long-term effects of in utero SSRI exposure on infant development and behavior are not known.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Due to pregnancy-induced physiologic changes, some pharmacokinetic parameters of paroxetine may be altered. The maternal CYP2D6 genotype also influences paroxetine plasma concentrations during pregnancy (Hostetter 2000; Ververs 2009).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The manufacturer suggests discontinuing paroxetine or switching to another antidepressant unless the benefits of therapy justify continuing treatment during pregnancy; consider other treatment options for women who are planning to become pregnant. The ACOG recommends that therapy with SSRIs or SNRIs during pregnancy be individualized; treatment of depression during pregnancy should incorporate the clinical expertise of the mental health clinician, obstetrician, primary health care provider, and pediatrician. The ACOG also recommends that therapy with paroxetine be avoided during pregnancy if possible and that fetuses exposed in early pregnancy be assessed with a fetal echocardiography (ACOG 2008). Other guidelines note that treatment with paroxetine should not be initiated in pregnant women (Bauer 2013). According to the American Psychiatric Association (APA), the risks of medication treatment should be weighed against other treatment options and untreated depression. The use of paroxetine is not recommended as first line therapy during pregnancy. For women who discontinue antidepressant medications during pregnancy and who may be at high risk for postpartum depression, the medications can be restarted following delivery (APA 2010). Treatment algorithms have been developed by the ACOG and the APA for the management of depression in women prior to conception and during pregnancy (Yonkers 2009).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Menopausal vasomotor symptoms do not occur during pregnancy; therefore, the use of paroxetine for the treatment of menopausal vasomotor symptoms is contraindicated in pregnant women.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Pregnant women exposed to antidepressants during pregnancy are encouraged to enroll in the National Pregnancy Registry for Antidepressants (NPRAD). Women 18 to 45 years of age or their health care providers may contact the registry by calling 844-405-6185. Enrollment should be done as early in pregnancy as possible.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054736\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Blood pressure, heart rate, liver and renal function. Monitor patient periodically for symptom resolution; monitor for worsening depression, suicidality, and associated behaviors (especially at the beginning of therapy or when doses are increased or decreased); signs and symptoms of serotonin syndrome; akathisia </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206554\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Paroxetine is a selective serotonin reuptake inhibitor, chemically unrelated to tricyclic, tetracyclic, or other antidepressants; presumably, the inhibition of serotonin reuptake from brain synapse stimulated serotonin activity in the brain</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206573\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Depression: The onset of action is within a week; however, individual response varies greatly and full response may not be seen until 8 to 12 weeks after initiation of treatment; antiobsessional and antipanic effects: Up to several weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Completely absorbed following oral administration</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: 8.7 L/kg (3 to 28 L/kg)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 93% to 95%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Extensively hepatic via CYP2D6 enzymes; primary metabolites are formed via oxidation and methylation of parent drug, with subsequent glucuronide/sulfate conjugation; nonlinear pharmacokinetics (via 2D6 saturation) may be seen with higher doses and longer duration of therapy. Metabolites exhibit ~2% potency of parent compound. C<sub>min</sub> concentrations are 70% to 80% greater in the elderly compared to nonelderly patients; clearance is also decreased.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Immediate release tablet and oral suspension have equal bioavailability</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Paxil: 21 hours; Paxil CR: 15 to 20 hours; Pexeva: 33.2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Capsules: Median: 6 hours (range: 3 to 8 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablets, oral suspension: Immediate release: Mean: 5.2 to 8.1 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablets: Controlled release: 6 to 10 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (64%, 2% as unchanged drug); feces (36% primarily via bile, &lt;1% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206577\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Brisdelle Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">7.5 mg (30): $234.25</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (PARoxetine Mesylate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">7.5 mg (30): $197.85</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Paxil Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/5 mL (250 mL): $365.77</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (PARoxetine HCl ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12.5 mg (30): $167.27</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (30): $174.56</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">37.5 mg (30): $179.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Paxil CR Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12.5 mg (30): $217.01</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (30): $226.47</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">37.5 mg (30): $233.27</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (PARoxetine HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (30): $78.56</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (30): $80.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (30): $84.44</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (30): $86.28</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Paxil Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (30): $210.69</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (30): $219.83</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (30): $226.48</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (30): $239.27</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Pexeva Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (30): $426.06</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (30): $442.91</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (30): $459.74</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (30): $476.63</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206580\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>A-Xat CR (KR);</li>\n      <li>Adepres (UA);</li>\n      <li>Afentan (LK);</li>\n      <li>Arapaxel (ES);</li>\n      <li>Arketis (CZ, LV, MT, RO);</li>\n      <li>Aropax (LU, MX, ZW);</li>\n      <li>Aropax 20 (AR, AU, BE, BR, NZ, PY, UY, ZA);</li>\n      <li>Aroxat (CL);</li>\n      <li>Dapagut (IT);</li>\n      <li>Daparox (ES);</li>\n      <li>Deroxat (CH, FR);</li>\n      <li>Divarius (FR);</li>\n      <li>Ennos (AT);</li>\n      <li>Euplix (DK);</li>\n      <li>Extine (AU);</li>\n      <li>Loxamine (NZ);</li>\n      <li>Lyuksotyl (UA);</li>\n      <li>Melev (BD);</li>\n      <li>Olane (PY);</li>\n      <li>Oxat (BD, LK);</li>\n      <li>Paluxon (HR);</li>\n      <li>Pari (LK);</li>\n      <li>PARI CR (IN);</li>\n      <li>Paroket (BD);</li>\n      <li>Parolex (CZ);</li>\n      <li>Paroser (IE);</li>\n      <li>Paroten (EC);</li>\n      <li>Parotin (BD, HK);</li>\n      <li>Parox (IE);</li>\n      <li>Paroxat (JO, KW, LB, QA, SA);</li>\n      <li>Paroxil CR (KR);</li>\n      <li>Paxan (CO);</li>\n      <li>Paxetil (KR);</li>\n      <li>Paxil (BB, BM, BS, BZ, CR, CU, DO, EC, GT, GY, HN, JM, MX, NI, PA, PR, RU, SR, SV, TR, TT, VE);</li>\n      <li>Paxil CR (BB, BM, BS, BZ, CR, DO, EC, GT, GY, HN, JM, KR, MX, NI, PA, PR, SR, SV, TT);</li>\n      <li>Paxitab (QA);</li>\n      <li>Paxtine (AU);</li>\n      <li>Paxxet (IL);</li>\n      <li>Reksetyn (UA);</li>\n      <li>Roxet (AU);</li>\n      <li>Seretran (EC);</li>\n      <li>Seretran CR (EC);</li>\n      <li>Seroxat (AE, AT, BD, BF, BH, BJ, CI, CN, CO, CY, CZ, DE, DK, EE, EG, ES, ET, FI, GB, GH, GM, GN, GR, HK, HR, HU, ID, IE, IL, IQ, IR, IS, IT, JO, JP, KE, KR, KW, LB, LR, LT, LU, LV, LY, MA, ML, MR, MT, MU, MW, MY, NE, NG, NL, NO, OM, PE, PH, PK, PL, PT, QA, RO, SA, SC, SD, SE, SG, SI, SK, SL, SN, SY, TH, TN, TW, TZ, UG, YE, ZM, ZW);</li>\n      <li>Seroxat CR (AE, BH, CN, HK, JO, KW, QA, SA, SG, TH);</li>\n      <li>Setine (TW);</li>\n      <li>Sumiko (VN);</li>\n      <li>Tagonis (DE);</li>\n      <li>Tiarix (PY);</li>\n      <li>Unirox (JO);</li>\n      <li>Xalexa (VN);</li>\n      <li>XET (TW);</li>\n      <li>Xet 20 (PH);</li>\n      <li>Xetanor (BG);</li>\n      <li>Xetine-P (TW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists, ACOG Practice Bulletin: Clinical Management Guidelines for Obstetricians-Gynecologists No. 92 April 2008 (Replaces Practice Bulletin Number 87, November 2007), &ldquo;Use of Psychiatric Medications During Pregnancy and Lactation,&rdquo; <i>Obstet Gynecol</i>, 2008, 111(4):1001-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/18378767/pubmed\" target=\"_blank\" id=\"18378767\">18378767</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Psychiatric Association (APA). Treatment recommendations for patients with major depressive disorder. 3rd ed. May 2010. Available at http://www.psychiatryonline.com/pracGuide/pracGuideTopic_7.aspx</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bauer M, Pfennig A, Severus E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. <i>World J Biol Psychiatry</i>. 2013;14(5):334-385.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/23879318/pubmed\" target=\"_blank\" id=\"23879318\">23879318</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bauer M, Whybrow PC, Anst J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 2: maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions. <i>World J Biol Psychiatry</i>. 2002;3(2):69-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/12479080/pubmed\" target=\"_blank\" id=\"12479080\">12479080</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berle JO, Spigset O. Antidepressant use during breastfeeding. <i>Curr Womens Health Rev</i>. 2011;7(1):28-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/22299006/pubmed\" target=\"_blank\" id=\"22299006\">22299006</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al, &ldquo;Selective Serotonin-Reuptake Inhibitors and Risk of Persistent Pulmonary Hypertension of the Newborn,&rdquo; <i>N Engl J Med</i>, 2006, 354(6):579-87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/16467545 /pubmed\" target=\"_blank\" id=\"16467545 \">16467545 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Diler RS and Avci A, &ldquo;Selective Serotonin Reuptake Inhibitor Discontinuation Syndrome in Children: Six Case Reports,&rdquo; <i>Current Therapeutic Reseach</i>, 2002, 63(3):188-97.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dopheide JA, &quot;Recognizing and Treating Depression in Children and Adolescents,&quot; <i>Am J Health Syst Pharm</i>, 2006, 63(3):233-43.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fava M. Prospective studies of adverse events related to antidepressant discontinuation. <i>J Clin Psychiatry</i>. 2006;67(Suppl 4):14-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/16683858/pubmed\" target=\"_blank\" id=\"16683858\">16683858</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Findling RL, Reed MD, and Blumer JL, &ldquo;Pharmacological Treatment of Depression in Children and Adolescents,&rdquo; <i>Paediatr Drugs</i>, 1999, 1(3):161-82.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Geller DA, Wagner KD, Emslie G, et al, &quot;Paroxetine Treatment in Children and Adolescents With Obsessive-Compulsive Disorder: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial,&quot; <i>J Am Acad Child Adolesc Psychiatry</i>, 2004, 43(11):1387-96.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/15502598/pubmed\" target=\"_blank\" id=\"15502598\">15502598</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Haddad PM. Antidepressant discontinuation syndromes. <i>Drug Saf</i>. 2001;24(3):183-197.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/11347722/pubmed\" target=\"_blank\" id=\"11347722\">11347722</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hendrick V, Stowe ZN, Altshuler LL, et al, &quot;Placental Passage of Antidepressant Medications,&quot; <i>Am J Psychiatry</i>, 2003, 160(5):993-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/12727706/pubmed\" target=\"_blank\" id=\"12727706\">12727706</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Horrigan JP and Barnhill LJ, &ldquo;Paroxetine-Pimozide Drug Interactions,&rdquo; <i> J Am Acad Child Adolesc Psychiatry</i>, 1994, 33(7):1060-1.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hostetter A, Stowe ZN, Strader JR Jr, et al, &quot;Dose of Selective Serotonin Uptake Inhibitors Across Pregnancy: Clinical Implications,&quot; <i>Depress Anxiety</i>, 2000, 11(2):51-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/10812529/pubmed\" target=\"_blank\" id=\"10812529\">10812529</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Keller MB, Ryan ND, Strober M, et al, &ldquo;Efficacy of Paroxetine in the Treatment of Adolescent Major Depression: A Randomized, Controlled Trial,&rdquo; <i>J Am Acad Child Adolesc Psychiatry</i>, 2001, 40(7):762-72.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lake MB, Birmaher B, Wassick S, et al, &ldquo;Bleeding and Selective Serotonin Reuptake Inhibitors in Childhood and Adolescence,&rdquo; <i>J Child Adolesc Psychopharmacol</i>, 2000, 10(1):35-8.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levinson-Castiel R, Merlob P, Linder N, et al, &quot;Neonatal Abstinence Syndrome After <i>in utero</i> Exposure to Selective Serotonin Reuptake Inhibitors in Term Infants,&quot; <i>Arch Pediatr Adolesc Med</i>, 2006, 160(2):173-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/16461873/pubmed\" target=\"_blank\" id=\"16461873\">16461873</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Markel H, Lee A, Holmes RD, et al, &ldquo;LSD Flashback Syndrome Exacerbated by Selective Serotonin Reuptake Inhibitor Antidepressants in Adolescents,&rdquo; <i>J Pediatr</i>, 1994, 125(5 Pt 1):817-9.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marshall AM, Nommsen-Rivers LA, Hernandez LL, et al, &quot;Serotonin Transport and Metabolism in the Mammary Gland Modulates Secretory Activation and Involution,&quot; <i>J Clin Endocrinol Metab</i>, 2010, 95(2):837-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/19965920/pubmed\" target=\"_blank\" id=\"19965920\">19965920</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Merlob P, Stahl B, and Sulkes J, &quot;Paroxetine During Breast-Feeding: Infant Weight Gain and Maternal Adherence to Counsel,&quot; <i>Eur J Pediatrm</i>, 2004, 163(3):135-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/14745552/pubmed\" target=\"_blank\" id=\"14745552\">14745552</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Misri S, Kim J, Riggs KW, Kostaras X. Paroxetine levels in postpartum depressed women, breast milk, and infant serum. <i>J Clin Psychiatry</i>. 2000;61(11):828-832.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/11105735/pubmed\" target=\"_blank\" id=\"11105735\">11105735</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Collaborating Centre for Mental Health (NCCMH). Depression: the treatment and management of depression in adults (updated edition). National Institute for Health &amp; Clinical Excellence (NICE). 2010.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/22132433/pubmed\" target=\"_blank\" id=\"22132433\">22132433</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nordeng H, Bergsholm YK, B&oslash;hler E, Spigset O. The transfer of selective serotonin reuptake inhibitors to human milk. <i>Tidsskr Nor Laegeforen</i>. 2001;121(2):199-203.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/11475200/pubmed\" target=\"_blank\" id=\"11475200\">11475200</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rabenda V, Nicolet D, Beaudart C, Bruy&egrave;re O, Reginster JY. Relationship between use of antidepressants and risk of fractures: a meta-analysis. <i>Osteoporos Int</i>. 2013;24(1):121-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/22638709/pubmed\" target=\"_blank\" id=\"22638709\">22638709</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rey-Sanchez F and Guitierrez-Cassares JR, &ldquo;Paroxetine in Children With Major Depressive Disorder: An Open Trial,&rdquo; <i>J Am Acad Child Adolesc Psychiatry</i>, 1997, 36(10):1443-7.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rizzoli R, Cooper C, Reginster JY, et al. Antidepressant medications and osteoporosis. <i>Bone</i>. 2012;51(3):606-613.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/22659406/pubmed\" target=\"_blank\" id=\"22659406\">22659406</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rosenberg DR, Stewart CM, Fitzgerald KD, et al, &quot;Paroxetine Open-Label Treatment of Pediatric Outpatients With Obsessive-Compulsive Disorder,&quot; <i>J Am Acad Child Adolesc Psychiatry</i>, 1999, 38(9):1180-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/10504818/pubmed\" target=\"_blank\" id=\"10504818\">10504818</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sachs HC, Committee On Drugs. The transfer of drugs and therapeutics into human breast milk: an update on selected topics. <i>Pediatrics</i>. 2013;132(3):e796-809.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/23979084/pubmed\" target=\"_blank\" id=\"23979084\">23979084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Safer DJ and Zito JM, &quot;Treatment Emergent Adverse Effects of Selective Serotonin Reuptake Inhibitors by Age Group: Children vs. Adolescents,&rdquo; <i>J Child Adolesc Psychopharmacol</i>, 2006, 16(1/2):159-69.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schatzberg AF, Blier P, Delgado PL, Fava M, Haddad PM, Shelton RC. Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research. <i>J Clin Psychiatry</i>. 2006;67(Suppl 4):27-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/16683860/pubmed\" target=\"_blank\" id=\"16683860\">16683860</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sharp SC and Hellings JA, &quot;Efficacy and Safety of Selective Serotonin Reuptake Inhibitors in the Treatment of Depression in Children and Adolescents: Practitioner Review,&quot; <i>Clin Drug Investig</i>, 2006, 26(5):247-55.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/17163258/pubmed\" target=\"_blank\" id=\"17163258\">17163258</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/19188870/pubmed\" target=\"_blank\" id=\"19188870\">19188870</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelton RC. Steps following attainment of remission: discontinuation of antidepressant therapy. <i>Prim Care Companion J Clin Psychiatry</i>. 2001;3(4):168-174.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/15014601/pubmed\" target=\"_blank\" id=\"15014601\">15014601</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sriraman NK, Melvin K, Meltzer-Brody S. ABM clinical protocol #18: use of antidepressants in breastfeeding mothers. <i>Breastfeed Med</i>. 2015;10(6):290-299.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/26204124/pubmed\" target=\"_blank\" id=\"26204124\">26204124</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stiskal JA, Kulin N, Koren G, et al, &ldquo;Neonatal Paroxetine Withdrawal Syndrome,&rdquo; <i>Arch Dis Child Fetal Neonatal Ed</i>, 2001, 84(2):F134-5.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Uguz F, Arpaci N. Short-term safety of paroxetine and sertraline in breastfed infants: a retrospective cohort study from a university hospital. <i>Breastfeed Med</i>. 2016;11:487-489.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/27575664/pubmed\" target=\"_blank\" id=\"27575664\">27575664</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wagner KD, Berard R, Stein MB, et al, &quot;A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Paroxetine in Children and Adolescents With Social Anxiety Disorder,&quot; <i>Arch Gen Psychiatry</i>, 2004, 61(11):1153-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/15520363/pubmed\" target=\"_blank\" id=\"15520363\">15520363</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wagner KD, &quot;Pharmacotherapy for Major Depression in Children and Adolescents,&quot; <i>Prog Neuropsychopharmacol Biol Psychiatry</i>, 2005, 29(5):819-26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/15908090/pubmed\" target=\"_blank\" id=\"15908090\">15908090</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Warner CH, Bobo W, Warner C, Reid S, Rachal J. Antidepressant discontinuation syndrome. <i>Am Fam Physician</i>. 2006;74(3):449-456.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/16913164/pubmed\" target=\"_blank\" id=\"16913164\">16913164</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weissman AM, Levy BT, Hartz AJ, et al, &quot;Pooled Analysis of Antidepressant Levels in Lactating Mothers, Breast Milk, and Nursing Infants,&quot; <i>Am J Psychiatry</i>, 2004, 161(6):1066-78.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/15169695/pubmed\" target=\"_blank\" id=\"15169695\">15169695</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ververs FF, Voorbij HA, Zwarts P, et al, &quot;Effect of Cytochrome P450 2D6 Genotype on Maternal Paroxetine Plasma Concentrations During Pregnancy,&quot; <i>Clin Pharmacokinet</i>, 2009, 48(10):677-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/19743889/pubmed\" target=\"_blank\" id=\"19743889\">19743889</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yonkers KA, Wisner KL, Stewart DE, et al, &ldquo;The Management of Depression During Pregnancy: A Report From the American Psychiatric Association and the American College of Obstetricians and Gynecologists,&rdquo; <i>Obstet Gynecol</i>, 2009, 114(3):703-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/19701065/pubmed\" target=\"_blank\" id=\"19701065\">19701065</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12681 Version 238.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709196\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F206594\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F50783091\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1054737\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1054730\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F206567\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F206551\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874764\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1054741\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49104563\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F206588\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1054740\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F206646\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F206643\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F206574\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F206555\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26045849\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F206630\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F206560\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F206589\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F206562\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F206578\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1054736\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F206554\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F206573\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F206577\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F206580\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12681|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=paroxetine-drug-information\" class=\"drug drug_general\">Paroxetine: Drug information</a></li><li><a href=\"topic.htm?path=paroxetine-patient-drug-information\" class=\"drug drug_patient\">Paroxetine: Patient drug information</a></li></ul></div></div>","javascript":null}